Czech and Slovak Ophthalmology 295 10.31348/2023/29 Review Diabetic Retinopathy and Diabetic Macular Edema – Screening Němčanský Jan https://orcid.org/0000-0003-1979-6419 Studnička Jan https://orcid.org/0000-0002-9911-4379 Vysloužilová Daniela https://orcid.org/0009-0008-0195-2456 Ernest Jan https://orcid.org/0009-0003-2775-7070 Němec Pavel https://orcid.org/0000-0002-4629-1283 20 9 2023 5 4

Diabetic retinopathy (DR) and diabetic macular edema (DME) are leading causes of severe visual loss in the working population. Therefore, both DR and DME have a significant socioeconomic and health impact, which taking into account the epidemiologic predictions is expected to increase. A crucial role in the management of DR and DME (not only for individuals, but also for the population) is played by an adequate screening program. This is based on the structure and organization of the healthcare system, the latest scientific developments in diagnostics (imaging) as well as technological advancements in computing (artificial intelligence, telemedicine) and their practical use. The recommendation presented by World Health Organization is also important. This paper evaluates all these factors, including evidence-based medicine reports and experience from existing DR and DME screening programs in comparable countries. Based on an evaluation of these parameters, recommended guidelines have been formulated for screening for DR and DME in the Czech Republic, including linkage to the Czech National Screening Center and the organization of the healthcare system.

 diabetic retinopathy diabetic macular edema recommended guidelines screening References World Health Organization. Regional Office for E. Screening programmes: a short guide. Increase effectiveness, maximize benefits and minimize harm. Copenhagen: World Health Organization. Regional Office for Europe; 2020. Diabetes is "a pandemic of unprecedented magnitude" now affecting one in 10 adults worldwide. Diabetes Res Clin Pract. 2021;181:109133. Yau JW, Rogers SL, Kawasaki R, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35(3):556- 564. Flaxel CJ, Adelman RA, Bailey ST, et al. Diabetic Retinopathy Preferred Practice Pattern®. Ophthalmology. 2020;127(1):P66-p145. doi: 10.1016/j.ophtha.2019.09.02510.1016/j.ophtha.2019.09.025 Kalvodová B, Sosna T, Ernest J, et al. Doporučené postupy pro diagnostiku a léčbu diabetické retinopatie. [Recommendations for diagnosis and therapy of diabetic retinopathy]. Cesk Slov Oftalmol. 2016;72(6):226-233. Czech. Wilson JMG, Jungner G, Organization WH. Principles and practice of screening for disease. 1968. Solomon SD, Chew E, Duh EJ, et al. Diabetic Retinopathy: A Position Statement by the American Diabetes Association. Diabetes Care. 2017;40(3):412-418. Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet. 2010;376(9735):124-136. Vseteckova P, Kvapil M, Majek O. Ná vrh doporuč eného diagnostického a klinického postupu pro program screeningu diabetické retinopatie a makulárního edému u pacientů s diabetem na národní úrovni Praha: Národní screeningové centrum; 2021 [Available National DM Register Notification (eHealth) DM diagnosis • General Practitioner • Internist • Diabetologist • Other Specialty Measures • Rescreening • Reading center • Reference to ophthalmologist • Vitreoretinal center Screening • (BC)VA • Retina exam • Biomicroscopy • Photography • AI from: https://nsc.uzis.cz/zdraveoci/res/file/dokumenty/navrh-doporuceneho-diagnostickeho-a-klinickeho-postupu-1.pdf. World Health Organization. Regional Office for E. Diabetic retinopathy screening: a short guide: increase effectiveness, maximize benefits and minimize harm. Copenhagen: World Health Organization. Regional Office for Europe; 2020. Grzybowski A, Brona P, Lim G, et al. Artificial intelligence for diabetic retinopathy screening: a review. Eye. 2020;34(3):451-460. Grzybowski A. Artificial intelligence for diabetic retinopathy screening. Acta Ophthalmologica. 2022;100(S275). Hristova E, Koseva D, Zlatarova Z, Dokova K. Diabetic Retinopathy Screening and Registration in Europe-Narrative Review. Healthcare (Basel). 2021;9(6). Kalvodová B, Sosna T, Řehák J, et al. Doporučené postupy pro diagnostiku a léčbu diabetické retinopatie. [Recommendations for diagnosis and therapy of diabetic retinopathy]. Cesk Slov Oftalmol. 2012;68(6):236-241. Czech. Všeobecná_zdravotní_pojišťovna. Informace o VZP výkonech 2022 [Available from: https://www.vzp.cz/poskytovatele/informace-pro-praxi/vykazovani-a-uhrady/informace-o-vzp-vykonech Schmidt-Erfurth U, Garcia-Arumi J, Bandello F, et al. Guidelines for the Management of Diabetic Macular Edema by the European Society of Retina Specialists (EURETINA). Ophthalmologica. 2017;237(4):185-222. England PH, England NHS. NHS diabetic eye screening (DES) programme: detailed information 2015 [updated 5.5.2021; cited 2023. Available from: https://www.gov.uk/topic/population-screening- -programmes/diabetic-eye. Grzybowski A, Brona P. Approval and Certification of Ophthalmic AI Devices in the European Union. Ophthalmol Ther. 2023. Nařízení evropského parlamentu a rady (EU) 2017/745 ze dne Wong TY, Sun J, Kawasaki R, et al. Guidelines on Diabetic Eye Care: The International Council of Ophthalmology Recommendations for Screening, Follow-up, Referral, and Treatment Based on Resource Settings. Ophthalmology. 2018;125(10):1608- 1622.